SCHEMBL1285708

SCHEMBL1285708

CC(C)(C)c1cccc(I)c1C(C)(C)C.O=S(=O)(O)c1c(F)c(F)c(F)c(F)c1F

nearest known ligand 0.33

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
CA2 P00918 1/20 0.33
HDAC11 Q96DB2 1/20 0.30
HDAC8 Q9BY41 1/20 0.30
HDAC6 Q9UBN7 1/20 0.30
GABRA1 P14867 1/20 0.30
GABRB2 P47870 1/20 0.30
HSD11B1 P28845 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6544073 0.83 CA2 (0.41) CA2GABRA1GABRB2HSD11B1
Trifluoromethanesulfonic Acid SCHEMBL1286190 0.82 CA2 (0.37) CA2GABRA1GABRB2HSD11B1
SCHEMBL1286248 0.79 HSD11B1 (0.40) HSD11B1
SCHEMBL29688753 0.78 CA2 (0.46) CA2GABRA1GABRB2
SCHEMBL1285882 0.78 CA2 (0.46) CA2GABRA1GABRB2
SCHEMBL31190270 0.77 FABP3 (0.56)
SCHEMBL15189392 0.77 CA2 (0.39) CA2GABRA1GABRB2HSD11B1
Hydrochloric Acid SCHEMBL5073192 0.76 CA2 (0.44) CA2GABRA1GABRB2
SCHEMBL379587 0.75 HSD11B1 (0.34) CA2HSD11B1
SCHEMBL5175740 0.74 CA2 (0.45) CA2GABRA1GABRB2HSD11B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10191371-B2 Underlayer composition and method of imaging underlayer ROHM AND HAAS ELECTRONIC MATERIALS LLC (US) 2019-01-29 US disclosed
US-10078263-B2 Underlayer composition and method of imaging underlayer composition DOW GLOBAL TECHNOLOGIES LLC (US) 2018-09-18 US disclosed
US-20140335454-A1 UNDERLAYER COMPOSITION AND METHOD OF IMAGING UNDERLAYER U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, AS NOTES COLLATERAL AGENT 2014-11-13 US disclosed
US-20140335455-A1 UNDERLAYER COMPOSITION AND METHOD OF IMAGING UNDERLAYER COMPOSITION U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, AS NOTES COLLATERAL AGENT 2014-11-13 US disclosed
US-8822124-B2 Underlayer composition and method of imaging underlayer composition DOW GLOBAL TECHNOLOGIES LLC (US) 2014-09-02 US disclosed
US-8822133-B2 Underlayer composition and method of imaging underlayer ROHM AND HAAS ELECTRONIC MATERIALS LLC (US) 2014-09-02 US disclosed
US-20120088192-A1 UNDERLAYER COMPOSITION AND METHOD OF IMAGING UNDERLAYER DOW GLOBAL TECHNOLOGIES LLC (US) 2012-04-12 US disclosed
US-20120088188-A1 UNDERLAYER COMPOSITION AND METHOD OF IMAGING UNDERLAYER COMPOSITION DOW GLOBAL TECHNOLOGIES LLC (US) 2012-04-12 US disclosed
US-7335787-B2 Method for producing onium salt derivatives, and novel onium salt derivatives TOYO GOSEI KOGYO CO., LTD. (JP) 2008-02-26 US disclosed
US-20050176982-A1 Method for producing onium salt derivatives, and novel onium salt derivatives TOYO GOSEI KOGYO CO., LTD. (JP) 2005-08-11 US disclosed
US-6620957-B1 Process for producing onium salt derivative and novel onium salt derivative TOYO GOSEI KOGYO CO., LTD. (JP) 2003-09-16 US disclosed
EP-1164127-A1 PROCESS FOR PRODUCING ONIUM SALT DERIVATIVE AND NOVEL ONIUM SALT DERIVATIVE Toyo Gosei Kogyo Co., Ltd. (JP) 2001-12-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050176982-A1 Method for producing onium salt derivatives, and novel onium salt derivatives STS, NANS, GRIK5 CA2 6/4885HDAC11 840/4885HDAC8 1234/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.